{"id":"NCT01467661","sponsor":"Shire","briefTitle":"Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia","officialTitle":"A Phase 3, Multi-centre, Open-label, Extension Study to Investigate the Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10-27","primaryCompletion":"2015-05-01","completion":"2015-05-01","firstPosted":"2011-11-09","resultsPosted":"2016-06-08","lastUpdate":"2021-06-09"},"enrollment":41,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Essential Thrombocythemia (ET)"],"interventions":[{"type":"DRUG","name":"SPD422 (anagrelide hydrochloride)","otherNames":["Xagrid","Agrylin"]}],"arms":[{"label":"SPD422 (anagrelide hydrochloride)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to provide SPD422 to subjects who completed Study SPD422 308 and, in the opinion of the Investigator, will continue to benefit from treatment.","primaryOutcome":{"measure":"Change From Baseline in Platelet Count at Final Assessment","timeFrame":"Baseline and final assessment (within 5 days of the last dose of investigational product)","effectByArm":[{"arm":"SPD422 (Anagrelide Hydrochloride)","deltaMin":1021.6,"sd":433.14}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":null},"locations":{"siteCount":16,"countries":["Japan"]},"refs":{"pmids":["30121892"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":53},"commonTop":["ANAEMIA","HEADACHE","NASOPHARYNGITIS","PALPITATIONS","DIARRHOEA"]}}